Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0001088875-25-000022·Adaptimmune Therapeutics PLC
Schedule 13G ownership disclosure
ADAPTIMMUNE THERAPEUTICS PLC
Common Stock · CUSIP: 00653A107
Event date: 2024-12-31
- Filing-level shares
- 70,914,570.00
- Percent of class
- 4.6%
- BAILLIE GIFFORD & CO
Shares: 70,914,570.00 · Class: 4.6%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001088875-25-000022
- Form type
- SCHEDULE 13G/A
- Filer
- Adaptimmune Therapeutics PLC
- CIK
- CIK 1621227
- Filed
- Feb 12, 2025
- Reporting period
- Dec 31, 2024
- Description
- Schedule 13G beneficial ownership